CD8A and neoplasm: found that blocking PI3Kγ with either genetic (p110γ‐/‐) or pharmacological (TG100‐115, a PI3Kγ inhibitor) promoted the repolarization of TAMs into M1‐like macrophages and thus activated tumor‐specific CD8+ T cells, which could effectively inhibit PDAC progression, invasion, metastasis, and desmoplasia.[149] Henau et al.